After reviewing the provided sources, there is no mention of age-based dosage adjustments for Cosentyx. Cosentyx (secukinumab) is a biologic medication used to treat certain autoimmune diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis.

According to the prescribing information provided by Novartis [2], the recommended dose for Cosentyx is 300 mg administered by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. For some patients, a starting dose of 150 mg may be used. However, there is no mention of age-based dosage adjustments.

Similarly, the Drug Patent Watch website [1] provides information on the patent status of Cosentyx, but does not provide any information regarding age-based dosage adjustments.

A review article published in the Journal of Clinical Medicine [3] discusses the use of Cosentyx in older adults and notes that there is limited data on the safety and efficacy of Cosentyx in this population. However, the article does not provide any information on age-based dosage adjustments.

In conclusion, based on the provided sources, there is no indication that age-based dosage adjustments are recommended for Cosentyx. However, it is important to consult with a healthcare provider to determine the appropriate dosage for individual patients.

Sources:
[1] Drug Patent Watch. Cosentyx. https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX. Accessed October 18, 2021.

[2] Novartis Pharmaceuticals Corporation. Cosentyx Prescribing Information. https://www.novartis.com/sites/www.novartis.com/files/cosentyx.pdf. Accessed October 18, 2021.

[3] Mehta NN, Yu Y, Poddubnyy D. Use of Secukinumab in Older Adults with Psoriasis and Psoriatic Arthritis: A Review of Current Evidence. J Clin Med. 2019;8(9):1386. doi:10.3390/jcm8091386.